Lamotrigine
- Generic Name
- Lamotrigine
- Brand Names
- Lamictal
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7Cl2N5
- CAS Number
- 84057-84-1
- Unique Ingredient Identifier
- U3H27498KS
- Background
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...
- Indication
Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients β₯2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...
- Associated Conditions
- Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
- Associated Therapies
- Conversion to monotherapy
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT00419003
- Locations
- πΊπΈ
Mount Sinai School of Medicine, New York, New York, United States
Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 180
- Registration Number
- NCT00412191
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
Study to Compare Two Formulations of Lamotrigine in Healthy Subjects
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 96
- Registration Number
- NCT00410371
- Locations
- πΊπΈ
GSK Investigational Site, Lincoln, Nebraska, United States
Clinical Evaluation of BW430C in Epilepsy
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 102
- Registration Number
- NCT00395694
- Locations
GSK Investigational Site
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
- Conditions
- First Posted Date
- 2006-08-03
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT00360126
- Locations
- π¦πΊ
GSK Investigational Site, New Farm, Queensland, Australia
A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures
- First Posted Date
- 2006-02-16
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00292461
- Locations
- π¨π³
National Cheng Kung University Hospital, Tainan, Taiwan, China
π¨π³Chang-Gung Memorial Hospital (CGMH), Taipei, Taiwan, China
π¨π³Changhua Christian Hospital, Changhua, Taiwan, China
Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency
- Conditions
- Interventions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 112
- Registration Number
- NCT00280293
- Locations
- πΊπΈ
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 660
- Registration Number
- NCT00280059
- Locations
- π¬π§
Pfizer Investigational Site, Treliske, Truro, Cornwall, United Kingdom
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-06-22
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 70
- Registration Number
- NCT00277641
- Locations
- πΊπΈ
Lindner Center of HOPE, Mason, Ohio, United States
Depression And Bipolar Disorder
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 221
- Registration Number
- NCT00274677
- Locations
- πΊπΈ
GSK Investigational Site, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.